Genetic-guided pharmacotherapy for venous thromboembolism: a systematic and critical review of economic evaluations.

ABSTRACT: Despite the known contributions of genes, genetic-guided pharmacotherapy has not been routinely implemented for venous thromboembolism (VTE). To examine evidence on cost-effectiveness of genetic-guided pharmacotherapy for VTE, we searched six databases, websites of four HTA agencies and citations, with independent double-reviewers in screening, data extraction, and quality rating. The ten eligible studies, all model-based, examined heterogeneous interventions and comparators. Findings varied widely; testing was cost-saving in two base-cases, cost-effective in four, not cost-effective in three, dominated in one. Of 22 model variables that changed decisions about cost-effectiveness, effectiveness/relative effectiveness of the intervention was the most frequent, albeit of poor quality. Studie

SUBMITTER: Lim KK 

PROVIDER: S-EPMC8602036 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature